The safety of antiviral therapy and drug withdrawal for the prevention of mother-to-child transmission of HBV during pregnancy

被引:13
作者
Xiao, Li-Xin [1 ]
Chen, Yi-Ru [2 ]
Huang, Ping [3 ]
Mei, Yong-Yu [1 ]
Pan, Calvin Q. [4 ,5 ]
Lin, Chao-Shuang [1 ]
机构
[1] Sun Yat Sen Univ, Dept Infect Dis, Affiliated Hosp 3, Guangzhou 510630, Guangdong, Peoples R China
[2] Sun Yat Sen Univ, Dept Gastroenterol & Hepatol, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China
[3] Peoples Hosp Lianjiang, Dept Infect Dis, Lianjiang, Guangdong, Peoples R China
[4] Capital Med Univ, Beijing Ditan Hosp, Ctr Liver Dis, Dept Med, Beijing, Peoples R China
[5] NYU, Dept Med, Div Gastroenterol & Hepatol, Langone Hlth,Sch Med, 132-21 41 Ave, New York, NY 11355 USA
关键词
antiviral therapy; drug withdrawal; hepatitis B virus; mother-to-child transmission; HEPATITIS-B-VIRUS; REDUCES PERINATAL TRANSMISSION; TENOFOVIR DISOPROXIL FUMARATE; SURFACE-ANTIGEN; INFECTION; EFFICACY; TELBIVUDINE; FLARES; WOMEN; PREDICTORS;
D O I
10.1002/jmv.26011
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The efficacy of prenatal antiviral therapy (AVT) for preventing the vertical transmission of hepatitis B virus (HBV) is well demonstrated. However, data are limited regarding the safety of postpartum cessation of AVT, which may induce alanine aminotransferase (ALT) elevation. We aimed to investigate the necessity of prolonging maternal AVT after delivery. Chronic hepatitis B mothers at the immune-tolerant phase with HBV DNA levels >6 log(10) IU/mL were prospectively enrolled and received AVT during the third trimester until delivery. Patients were offered to discontinue AVT either at delivery or postpartum week (PPW) 6. In addition, mothers who deferred AVT during pregnancy served as the control group. All mothers were followed until PPW 52 for clinical and virological parameters of hepatitis flares. Among 118 mothers recruited, 91 received AVT with 53 (group A) and 24 (group B) discontinue their treatment at delivery and PPW 6, respectively. Twenty-seven mothers who deferred AVT during pregnancy were followed as the control (group C). A total of 104 of 118 mothers who completed the study, 50% (52/104) had postpartum-elevated ALT levels, which were mild and moderate except 6 of 104 (5.77%) of patients had levels >= 5 times the upper limit of normal; 70% (36/52) of the ALT flares occurred within 12 weeks after delivery. In subgroup analyses, the frequency of ALT elevation was similar among the groups A vs B vs C (50.9% [27/53] vs 58.3% [14/24] vs 40.7% [11/27], respectively;P = .447), as well as the mean peak ALT level (108.4/74.1/126.7 U/L in groups A/B/C, respectively;P = .291). Although postpartum ALT flares were common for mothers with or without AVT during pregnancy, most cases of ALT elevation were mild to moderate. Our study observed that extending AVT to PPW 6 did not affect maternal outcomes and ATV should be discontinued at birth. Close monitoring is warranted as severe flares rarely occurred.
引用
收藏
页码:3381 / 3389
页数:9
相关论文
共 37 条
  • [1] Angel Garcia Alonso L, 2006, Ann Hepatol, V5, P184
  • [2] BEASLEY RP, 1983, LANCET, V2, P1099
  • [3] Total Alanine Aminotransferase (ALT) Flares in Pregnant North American Women With Chronic Hepatitis B Infection: Results From a Prospective Observational Study
    Bzowej, Natalie H.
    Tran, Tram T.
    Li, Ruosha
    Belle, Steven H.
    Smith, Coleman I.
    Khalili, Mandana
    Chung, Ray
    Tsai, Naoky
    Terrault, Norah
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 (08) : 1283 - 1291
  • [4] Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-to-infant transmission of hepatitis B virus
    Chen, Huey-Ling
    Lee, Chien-Nan
    Chang, Chin-Hao
    Ni, Yen-Hsuan
    Shyu, Ming-Kwang
    Chen, Shih-Ming
    Hu, Jen-Jan
    Lin, Hans Hsienhong
    Zhao, Lu-Lu
    Mu, Shu-Chi
    Lai, Ming-Wei
    Lee, Chyi-Long
    Lin, Hsien-Ming
    Tsai, Ming-Song
    Hsu, Jenn-Jeih
    Chen, Ding-Shinn
    Chan, K. Arnold
    Chang, Mei-Hwei
    [J]. HEPATOLOGY, 2015, 62 (02) : 375 - 386
  • [5] Dynamic changes of HBV markers and HBV DNA load in infants born to HBsAg(+) mothers: can positivity of HBsAg or HBV DNA at birth be an indicator for HBV infection of infants?
    Chen, Tianyan
    Wang, Jing
    Feng, Yuling
    Yan, Zhi
    Zhang, Tieying
    Liu, Minghui
    Bai, Yun
    Song, Hongxia
    Liu, Hongli
    Yang, Yuan
    Liu, Jinfeng
    He, Yingli
    Chen, Yunru
    Zhang, Shulin
    Zhuang, Guihua
    Liang, Xiaofeng
    Liu, Zongyin
    Xu, Xiaguang
    Chen, Wei
    Liu, Yong
    Zhao, Yingren
    [J]. BMC INFECTIOUS DISEASES, 2013, 13
  • [6] Hepatitis B in pregnancy screening, treatment, and prevention of vertical transmission
    Dionne-Odom, Jodie
    Tita, Alan T. N.
    Silverman, Neil S.
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2016, 214 (01) : 6 - 14
  • [7] EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
    Lampertico P.
    Agarwal K.
    Berg T.
    Buti M.
    Janssen H.L.A.
    Papatheodoridis G.
    Zoulim F.
    Tacke F.
    [J]. JOURNAL OF HEPATOLOGY, 2017, 67 (02) : 370 - 398
  • [8] Flares in chronic hepatitis B patients induced by the host or the virus?: Relation to treatment response during Peg-interferon α-2b therapy
    Flink, HJ
    Sprengers, D
    Hansen, BE
    van Zonneveld, M
    de Man, RA
    Schalm, SW
    Janssen, HLA
    [J]. GUT, 2005, 54 (11) : 1604 - 1609
  • [9] Hepatitis B: Epidemiology and prevention in developing countries
    Franco, Elisabetta
    Bagnato, Barbara
    Marino, Maria Giulia
    Meleleo, Cristina
    Serino, Laura
    Zaratti, Laura
    [J]. WORLD JOURNAL OF HEPATOLOGY, 2012, 4 (03) : 74 - 80
  • [10] Immunological tolerance of the human fetus
    Gaunt, G
    Ramin, K
    [J]. AMERICAN JOURNAL OF PERINATOLOGY, 2001, 18 (06) : 299 - 312